The bio-tech industry has been buzzing with noteworthy developments involving
Amgen (AMGN). On the business side, there have been robust investments in Amgen's stocks, including significant contributions from CapWealth Advisors LLC and Koshinski Asset Management Inc. Additionally, Amgen announced the launch of AmgenNow, followed by a memorable stock price rise of 6%. FDA's approval of a new use for Amgen's Tezspire and declaring systemic sclerosis treatment as an orphan status also escalated Amgen's stature in the market.
Amgen's strong revenue growth, supported by the breakthrough cardiovascular study, has come under Oppenheimer's spotlight. The substantial share purchases and the company's strong institutional backing was inspiring.
Amgen's beat on Q2 Earnings and revenue estimates boosted the investor sentiment. Furthermore, the company announced a third-quarter dividend of $2.38. Despite some divestments, the overall performance and promise of Amgen's therapies pipeline led analysts to maintain a bullish outlook.
Amgen is eyeing expansion with a $650M facility in Puerto Rico and plans to invest over half a billion dollars in a new Science and Innovation Center, denoting strong forward-thinking.
Amgen AMGN News Analytics from Tue, 24 Jun 2025 07:00:00 GMT to Sat, 18 Oct 2025 10:49:50 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor -2
